Conversely, mepolizumab and reslizumab, which selectively block circulating IL-5, and benralizumab, which prevents the adhesion of IL-5 to the IL-5Rα chain, may indirectly modulate the contractile properties of ASMCs by targeting eosinophils and other immunomodulatory effector cells responsible for promoting inflammatory processes of asthma. The gene discussed is IL5; the disease is asthma.